Poland· PL-100487781

Abrysvo

A respiratorisches-synzytial-virus impfstoffe product containing szczepionka przeciw syncytialnemu wirusowi oddechowemu (rsv) (biwalentna, rekombinowana), registered in Poland by Pfizer Europe MA EEIG. The same ATC class is registered in 11 of our 19 countries.

ATC J07BX05

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAbrysvoATCJ07BX05REGISTER NO.PL-100487781PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Respiratorisches-synzytial-virus impfstoffe is registered in 11 of 19 countries.

Countries holding a registration under ATC J07BX05 (respiratorisches-synzytial-virus impfstoffe), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose

Respiratorisches-synzytial-virus impfstoffe · ATC J07BX05

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Szczepionka przeciw syncytialnemu wirusowi oddechowemu (RSV) (biwalentna, rekombinowana)
Manufacturer
Pfizer Europe MA EEIG
Country
Poland (PL)
ATC code
J07BX05
ATC class
Respiratorisches-Synzytial-Virus Impfstoffe
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

1 priced
  • gtin
    05415062116210
    1 fiol. proszku + amp.-strzyk. z rozpuszczalnikiem + adapter fiolki + igła
    PLN 817.72

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/6d8a7fea-e083-4adf-ad4e-671ca8b0743e
GET /v1/drugs/6d8a7fea-e083-4adf-ad4e-671ca8b0743e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań",
  "source": "urpl",
  "strength": "-",
  "packaging": "05415062116210 ¦ Rp ¦ EU/1/23/1752/001 ¦ 151291\n1 igła  + 1 adapter fiolki ¦ 1 fiol.  z proszkiem ¦ 1 amp.-strzyk.  z rozp.\nRp ¦ EU/1/23/1752/003 ¦ 151292\n5 amp.-strzyk.  z rozp. ¦ 5 fiol.  z proszkiem ¦ 5 igła  + 5 adapterów fiolki\nRp ¦ EU/1/23/1752/005 ¦ 151293\n10 igła  + 10 adapterów fiolki ¦ 10 amp.-strzyk.  z rozp. ¦ 10 fiol.  z proszkiem\nRp ¦ EU/1/23/1752/002 ¦ 151528\n1 fiol.  z proszkiem ¦ 1 amp.-strzyk.  z rozp. + 1 adapter fiolki\nRp ¦ EU/1/23/1752/006 ¦ 151529\n10 fiol.  z proszkiem ¦ 10 amp.-strzyk.  z rozp. + 10 adapterów fiolki\nRp ¦ EU/1/23/1752/004 ¦ 151530\n5 amp.-strzyk.  z rozp. + 5 adapterów fiolki ¦ 5 fiol.  z proszkiem\nRp ¦ EU/1/23/1752/007 ¦ 162292\n5 fiol.  z proszkiem ¦ 5 fiol.  z rozp. (opakowanie 5-cio dawkowe)\nRp ¦ EU/1/23/1752/008 ¦ 162293\n10 fiol.  z proszkiem ¦ 10 fiol.  z rozp. (opakowanie 10-cio dawkowe)",
  "substance": null,
  "common_name": "Szczepionka przeciw syncytialnemu wirusowi oddechowemu (RSV) (biwalentna, rekombinowana)",
  "pl_product_id": "100487781",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about respiratorisches-synzytial-virus impfstoffe.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.